Search results
What Direction Does Merck & Co Inc (NYSE: MRK) Analysts Think The Company Will Take? – Stocks...
Stocks Register· 3 days agoThe trading price of Merck & Co Inc (NYSE:MRK) remained unchanged on Tuesday, April 23, closing at $126.88. The company’s P/E ratio in the trailing 12-month ...
Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Proactive Investors· 2 days agoMerck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after...
Merck Raises Forecast as Sales of Its Cancer Immune Therapy Soar
Bloomberg· 2 days agoMerck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
WSAU Wausau· 2 days agoBy Patrick Wingrove (Reuters) - Merck & Co on Thursday raised its annual profit and revenue forecast...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 2 days agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Reuters via AOL· 2 days ago(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecast on the back of...
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%
Simply Wall St. via Yahoo Finance· 6 days ago(NYSE:MRK) can tell us which group is most powerful. The group holding the most number of shares in...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Reuters via Yahoo Finance· 2 days ago(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 1 day agoOn Friday, Wells Fargo adjusted its outlook on shares of pharmaceutical giant Merck & Co., Inc....
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 2 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...